Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
|Slideshows|August 31, 2016
Diabetes Disparities and Differences
Author(s)Leo Robert
Wild variations in treatment success and how T2D differs in youth and adults top the diabetes news. Click inside for highlights.
Advertisement
Top diabetes headlines: effective treatment rates vary wildly around US, how type 2 differs in youth and adults, antidiabetes Rx’s outpace antiobesity, old drugs perform new tricks-these are just a few of the more significant recent findings.Click on the slides above for highlights of the latest diabetes news.
References:
Advertisement
Related to this article
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
FDA authorized Abbott’s Libre Duo 10 Day system, the first wearable device to continuously monitor both glucose and ketones.
Insulin icodec is now available in the US after FDA approval, offering adults with type 2 diabetes a once-weekly basal insulin option.
Advertisement
Advertisement
Trending on Patient Care Online
1
ASH Raises Ferritin Thresholds for Diagnosing Iron Deficiency
2
Combating Prostate Cancer Misconceptions in Primary Care: An Expert Discussion
3
Endocrine Society Obesity Statement Calls for Goals Beyond Weight Loss
4
FDA Approves Finerenone for CKD Associated With Type 1 Diabetes
5